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Accurate and precisely measured GFR values are clinically ne-
cessary for renal function-speciﬁc subsets of the CKD popula-
tion [1] and also serve as primary end points in clinical trials
investigating treatment effects on the rate of GFR loss [2, 3].
Precise GFR slope differences therefore have the potential to
provide an approval pathway for new drugs for prevention of
CKD progression with reasonable sample size. Numerous stud-
ies have found from both cross-sectional and longitudinal data
that serum creatinine-based measurements of estimated GFR
(eGFR) exhibit excessive inaccuracy leading to recommenda-
tions for the use of measured GFR (mGFR), particularly
when measuring the rate of progression of CKD [4, 5].
The choice of mGFR method for achievement of the desired
accuracy and precision is not straightforward.MeasuredGFRcan,
in general, be performed either as a urinary clearance during con-
stant infusion of a GFRmarker (e.g. inulin, iothalamate or iohex-
ol) or as a plasma clearance performed during either constant
infusion (assuming constant urinary excretion and GFR) or as
a single injection with calculation of GFR based on injected
dose and an estimated AUC (area under the curve, assuming a
constantGFRovermany hours). In both adult [6, 7] and pediatric
[8] CKD patients, the precision of mGFR has been reported to be
better with plasma clearance methods due to the observed high
variation inGFRmarker urinary excretion rate, attributed to vari-
able bladder emptying with incomplete sampling. However, the
urinary clearance method when used with a bladder emptying
correction based on a constant infusion of ortho-iodohippurate
(OIH, hippuran, 100% renal clearance without metabolism) pro-
vides superior values for intra-test and inter-test precision (1.9
and 2.9%) and is supported by the accuracy (lack of bias versus
simultaneous inulin urinary clearance) of iothalamate as a GFR
solute [9] as well as superior precision of the slope of GFR decline
(SEM <1 mL/min/year) for use in longitudinal studies necessary
for drug approval and for clinicalmanagement/treatment of renal
risk factors in individual patients [10].
A substantial problem with the use of the best urinary clear-
ance methods for GFR in clinical and multi-center research set-
tings, despite their robust qualiﬁcations as a ‘gold standard’ [10],
is the use of radioactive solutes for constant infusion urinary
clearance which includes radiolabeled OIH for correcting
mGFR values for variable bladder emptying. Unfortunately, no
validated non-radioactive bladder emptying-corrected GFR
data have been reported, with para aminohippurate rendered un-
suitable due to its metabolism. Bladder emptying variance is like-
ly of greatermagnitude in the enlarging elderly subset of theCKD
population. Accordingly, there would be great clinical and re-
search value in achieving a validated non-radioactive version of
the Apperloo et al.mGFRmethod [10] using non-radioactive in-
fusions of iothalamate or iohexol with non-radioactive OIH that
might demonstrably approach that method’s reported precision
both for individual GFR measurements and GFR slopes.
Given the unmet need for non-radioactive validated mGFR
methods that minimize or eliminate bladder emptying vari-
ance, there is an expected widespread interest in plasma clear-
ance methods that obviate urine collection. Single injection
plasma clearance mGFR calculations depend on true GFR re-
maining constant during the hours of measurement of GFR
marker decay in plasma specimens and, while this has been
observed in some reports over 2–3 h intervals [6, 7], there is
abundant evidence for large diurnal variation in true GFR in
both normal subjects and CKD patients as exempliﬁed by a
rising inulin clearance and falling plasma inulin level during
late morning and afternoon during constant inulin infusion
and rigorous control of protein intake (Figure 1) [11, 12]. In
the current issue of NDT, Ebert et al. [13] provide a potential
time- and convenience-improving method to estimate mGFR
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(mGFR = IV dose of iohexol/AUC0 to inf ) as the plasma clear-
ance of iohexol after a single IV injection. The authors have
derived an estimating equation to empirically adjust mGFR va-
lues calculated from plasma iohexol levels obtained over a 5-h
sampling period to a value designed to approximate a hypothet-
ically more accurate value based on 24-h blood sampling. If fu-
ture studies can provide validation of this equation to a ‘gold
standard’ mGFR method (e.g. Apperloo et al. [10]), then this
equation could, in theory, simplify mGFR measurements.
Both Ebert et al. [13] and prior studies [14, 15] of mGFR
based on single injection iothalamate or iohexol plasma clear-
ances have found that a shorter duration of plasma level mea-
surements (2–9 h) leads to large and clinically meaningful
overestimations of mGFR as compared to that derived from a
longer sampling interval (10–24 h). As their basis for choosing
the primacy of a 24-h iohexol plasma clearance sampling peri-
od, Ebert et al. [13] have cited a comparison of 4, 6 and 24-h
plasma clearance sampling periods undertaken with validation
versus simultaneous (ﬁrst 6-h post-IV iohexol) urinary clear-
ance measurements in 343 renal transplant patients with a
mean iohexol urinary mGFR of 49 mL/min/1.73 m2 [15].
These allograft results demonstrated a substantial ‘overesti-
mation’ of plasma clearance mGFR, as compared to a 5-h urin-
ary mGFR (using a falling post-injection plasma iohexol
concentration) for both the 4-h (+27.2%) and 6-h (+20.6%)
plasma clearance sampling periods, but found that a 24-h sam-
pling period reduced the ‘overestimation’ to a more modest
value (+6.8%) and concluded that a 24-h sampling period is ne-
cessary for accuracy in subjects with reduced mGFR. Stolz et al.
[15] did not consider diurnal or meal-related GFR effects on
mGFR in explaining their ‘overestimation’ of mGFR in their
4- and 6-h (early AUC) versus 24-h (long duration) AUC as
compared to their early 5-h urinary clearance. Stolz et al. [15]
also did not consider the reported ﬁnding that a non-steady
state (falling) plasma GFR marker level causes the urinary
mGFR to falsely overestimate values found in a steady state
mGFR, a reported methodological confounder of mGFR
accuracy in the MDRD study [16]. This error is due to the
delay in glomerular marker transit time from glomerulus to
bladder urine during rapid fall in venous plasma GFR marker
concentration after IV or even SQ injection during a timed
urinary clearance period and is accompanied by an additional
error due to generation of an arteriovenous gradient (arterial
level > mixed venous blood sample) created by the rapid and
un-replaced renal loss of GFR marker from ﬁltered plasma
[16–18].
Ebert et al. [13] are correct in pointing out that normal di-
urnal variation in mGFR, as accompanied by parallel diurnal
changes in renal plasma ﬂow, may be a factor in explaining
the 5-h plasma clearance value exceeding the corresponding
24-h value. Although not as pronounced as in an animal model
(hummingbird [19]), there is a large and consistent diurnal in-
crease in mGFR during the late morning and afternoon in nor-
mal andCKDhuman subjects [11, 12, 20], CKDpatients [11, 21]
and in renal allografts [22], and it remains evident even when
diet protein intake is carefully controlled and administered
steadily every 3-h [11, 12, 22]. Protein intake, per se, also causes
large acute increases in mGFR [23, 24]. Both the diurnal and
diet protein effects on mGFR are independent of systemic
blood pressure [11, 12, 24].
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F IGURE 1 : Time course of plasma inulin and inulin clearance (A) and of plasma para aminohippurate (PAH) concentration and PAH clearance
(B) in a representative CKD patient. Symbols refer to differing methods of calculation: square, 24-h constant infusion method with clearance =
infusion rate/plasma concentration; triangle, urinary clearance = urinary excretion rate/plasma concentration; circle, modiﬁed constant infusion
method with adjustment for accumulating solute when plasma concentration is changing. Reproduced from Van Acker et al. [11].
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Accordingly, when applied to the data of Ebert et al. [13],
with a reported average iohexol injection time of ∼9:30 am
and the 5-h sample time at ∼2:30 pm, it might be predicted
(Figure 1) that the reported late morning and afternoon rise
in GFR, plus the potential for random protein meals, will in-
crease true GFR in that time interval such that the 5-h proced-
ure may not be ‘overestimating’ mGFR, but simply reﬂect
expected physiology. Similarly, acceptance of the 24-h iohexol
plasma GFR values obligates one to accept both intrinsic varia-
tions in diurnal (afternoon/evening) increases in true GFR as
well as diet protein-induced variations in GFR. While a 24-h
mGFR by single injection plasma clearance may have value in
reﬂecting ‘real world’ conditions, it has the major disadvantage
of introducing a loss of accuracy and precision that is gained by
shorter measurements under standardized physiological condi-
tions. That is, it is important to decide whether the goal is to
measure GFR under conditions designed to increase variance
such as long (>2–4 h) or varying time of day clearance periods
and with potentially random diet protein effects or to pursue
the goal to remove as much of the protein and diurnal variation
as possible. This has been approximated previously by starting a
urinary clearance procedure 2-h following a ﬁxed low protein
breakfast followed by fasting, with clearance periods commen-
cing 2-h post-meal, with clearance periods not exceeding 2-h
and occurring at a ﬁxed time of day [10]. The future addition
of a validated non-radioactive method to minimize bladder-
emptying variance during urinary clearance periods might be
an optimal solution for both clinical and clinical research
needs and thereby avoid the need for single injection mGFR
measurements that are subject to large diurnal and protein
intake GFR contributions.
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